D
Douglas J. Watson
Researcher at Merck & Co.
Publications - 61
Citations - 4581
Douglas J. Watson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Rofecoxib & Etoricoxib. The author has an hindex of 28, co-authored 61 publications receiving 4426 citations. Previous affiliations of Douglas J. Watson include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
M. J. S. Langman,Dennis M. Jensen,Douglas J. Watson,Sean E. Harper,Peng-Liang Zhao,Hui Quan,James A. Bolognese,Thomas J. Simon +7 more
TL;DR: Treatment with rofecoxib was associated with a significantly lower incidence of PUBs than treatment with NSAIDs, based on survival analysis of time to first PUB diagnosis, using Pubs that met pre-specified criteria judged by a blinded, external adjudication committee.
Journal ArticleDOI
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Antonio M. Gotto,Edwin J. Whitney,Evan A. Stein,Deborah R. Shapiro,Michael Clearfield,Stephen E. Weis,Jesse Y. Jou,Alexandra Langendorfer,Polly A. Beere,Douglas J. Watson,John R. Downs,John S. de Cani +11 more
TL;DR: People with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification, and on-treatment apoB, especially when combined with apoAI to form the apOB/AI ratio, may be a more accurate predictor than LDL- C of risk for first AMCE.
Journal Article
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Elliot W. Ehrich,Glenn M. Davies,Douglas J. Watson,James A. Bolognese,Beth C. Seidenberg,Nicholas Bellamy +5 more
TL;DR: In this analysis, mean changes of roughly 9 to 12 mm (100 mm normalized visual analog scale, VAS) on WOMAC scales were perceptible changes to patients with hip and knee OA.
Journal Article
All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database
TL;DR: Compared to patients with OA and those with no arthritis, patients with RA had a higher age and gender adjusted incidence of all-cause mortality and of major vascular events during almost 5 years of followup.
Journal ArticleDOI
Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.
TL;DR: In this paper, the authors examined the risk of acute thromboembolic cardiovascular events (TCEs) with current naproxen use among patients with rheumatoid arthritis.